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We determined the agr type, multilocus sequence
type, protein A gene type (spa typing), toxin gene profile,
and antimicrobial drug resistance profile of 469 isolates of
Panton-Valentine leukocidin–positive community-acquired
methicillin-resistant Staphylococcus aureus isolates (PVL-
positive CA-MRSA). The isolates had been collected from
around the world from 1999 through 2005 by the French
National Reference Center for Staphylococci. We found
that some continent-specific clones described in 2003,
such as clone ST8, have now spread all over the world.
Likewise, some PVL-positive CA-MRSA have spread to
several countries on various continents. New clones have
emerged (e.g., ST377) on new genetic backgrounds. PVL-
positive CA-MRSA that were usually susceptible to most
antistaphylococcal antimicrobial agents have acquired new
resistance determinants (e.g., to gentamicin) in certain
countries. The major trait shared by all these clones is a
short staphylococcal chromosomal cassette mec element
of type IV or V.
By definition, community-acquired methicillin-resist-ant Staphylococcus aureus (CA-MRSA) strains infect
patients with no risk factors for acquiring an MRSA strain
of hospital origin. CA-MRSA infections usually affect
previously healthy young patients (1). These infections
are mostly of skin and soft tissue, but deep-seated infec-
tions such as necrotizing pneumonia and disseminated
invasive osteomyelitis have been described (2). Many
CA-MRSA isolates produce Panton-Valentine leukocidin
(PVL) and harbor a type IV staphylococcal chromosomal
cassette mec (SCCmec) element, but some isolates harbor-
ing the SCCmec V element have been reported (3). PVL-
positive CA-MRSA clones have spread throughout the
world (4).
In 2003, Vandenesch et al. described continent-specif-
ic PVL-positive CA-MRSA clones (mainly on an agr3
background) and characterized them by their sequence
type (ST) (4). The main European clone, ST80, was detect-
ed in France, Switzerland, the Netherlands, England,
Belgium, and Germany (5,6), but also in northern Europe
(e.g., Denmark), where MRSA strains are rare in hospitals
(7). One of the most prevalent PVL-positive CA-MRSA
clones in the United States (USA300) belongs to ST8 (8);
other US clones include USA400 (ST1), USA1000
(ST59), and USA1100 (ST30) (9). ST30 is also a major
clone in Asia and Oceania (10,11) and is referred to as the
South West Pacific clone (11). In Singapore, an interna-
tional travel hub, several clones belonging to ST80, ST30,
and ST59 have been reported (12). The prevalence of
PVL-positive CA-MRSA varies considerably from conti-
nent to continent. In the United States, MRSA were isolat-
ed from 50% of patients with skin and soft-tissue
infections seen in emergency departments of 11 cities
(97% of isolates belonged to clone USA300) (13). In
Europe, the prevalence is lower, at ≈1–3% (14).
Since 1999, the French National Center for
Staphylococci has characterized 469 PVL-positive CA-
MRSA isolates collected throughout the world. The iso-
lates were typed by multilocus sequence type (MLST),
protein A gene type (spa typing), antimicrobial drug resist-
ance profiling, and toxin and resistance gene analysis.
We describe the evolution and spread of PVL-positive CA-
MRSA clones since their initial description.
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Materials and Methods
Bacterial Isolates
From 1999 through 2005, the French National
Reference Center for Staphylococci received 469 PVL-
positive CA-MRSA isolates from 17 countries. These iso-
lates were voluntarily sent to the center for PVL for gene
detection and genomic characterization (clone designa-
tion). A single strain was selected per patient. Twenty-two
isolates corresponded to an outbreak linked to a maternity
unit that occurred in France in 2002–2003.
DNA Extraction and Identification of agr Alleles
The strains were grown on brain–heart infusion agar
or in brain–heart infusion broth at 37°C overnight.
Genomic DNA was extracted with a standard procedure
(15). Amplification of gyrA was used to confirm the qual-
ity of each DNA extract and the absence of PCR inhibitors.
All PCR products were analyzed by electrophoresis on
ethidium bromide–stained 1% agarose gels (Sigma, Lyon,
France). The agr group (agr 1–4) was determined by PCR
as previously described (15).
Detection of the mecA Gene and  SCCmec Typing
The mecA gene (coding for methicillin resistance) was
detected by PCR as previously described (3). The staphy-
lococcal chromosomal cassette mec (SCCmec I-IV) was
detected as described by Oliveira et al. (16), and SCCmec
type V was detected as previously described (3). The fol-
lowing reference strains were used as controls: COL
(SCCmec I), BK2464 (SCCmec II), HU106 (SCCmec III),
and BK2529 (SCCmec IV).
Detection of Toxin Genes
Using PCR, we determined the presence of 22 specif-
ic staphylococcal virulence genes, as described previously
(15,17). We detected sequences specific for staphylococcal
enterotoxin genes (sea-e, seh, sek, sem, seo), as well as the
toxic-shock syndrome toxin gene (tst), exfoliative toxin
genes (eta, etb, etd), PVL genes (lukS-PV–lukF-PV),
LukE–lukD leukocidin genes (lukE–lukD), the class F
lukM leukocidin gene (lukM), hemolysin genes (gamma
[hlg], gamma variant [hlgv] and β [hlb]), and epidermal
cell differentiation inhibitor genes (edinA/B/C).
Antimicrobial Susceptibility Testing
MICs of penicillin, oxacillin, cefoxitin, kanamycin,
tobramycin, gentamicin, erythromycin, clindamycin, tetra-
cycline, pristinamycin, ofloxacin, fusidic acid, van-
comycin, teicoplanin, fosfomycin, trimethoprim/sulfa-
methoxazole, rifampin, mupirocin, quinupristin/dalfo-
pristin, and linezolid were determined by using the stan-
dard agar dilution technique, as recommended by the
French Society for Microbiology. Structural genes for
resistance to tetracycline, aminoglycosides, and
macrolide-lincosamide-streptogramin (18) were identified
by PCR. DNA was amplified in a model 2400 thermal
cycler (Perkin-Elmer Cetus, Norwalk, CT, USA) with Taq
(Qbiogene, Inc., Carlsbad, CA, USA) or Pfu (Stratagene,
La Jolla, CA, USA) DNA polymerase, as recommended by
the manufacturers. PCR elongation times and temperatures
were adjusted to the expected size of the PCR product and
to the nucleotide sequences of the primers, respectively.
spa Typing
spa typing was performed on PVL-positive MRSA
isolates as previously described (19). The x region of the
spa gene was amplified by PCR. spa types were deter-
mined with the Ridom Staph Type software (Ridom
GmbH, Würzburg, Germany), which automatically detects
spa repeats and assigns a spa type according to Harmsen et
al. (20) (http://spaserver.ridom.de). When the recently
developed algorithm BURP (Based Upon Repeat Patterns)
was applied, spa types were clustered into different groups
with calculated cost between members of a group <6. spa
types shorter than 3 repeats were excluded from analysis
because no reliable deduction about ancestries can be
made from these types. In addition to point mutation
events, the new algorithm takes all other modifications that
can occur (repeat or duplication or deletion) into account
when the relatedness of different spa types is calculated.
Because of speed constrains, a heuristic version of the
EDSI-Alignment (Excisions, Duplications, Substitutions,
Insertions), as described by Sammeth et al., was used (21).
BURP spa clonal complexes (spa-CC) were automatically
assigned by the Ridom Staph Type software (www.ridom.
de/staphtype/).
MLST
MLST was performed on representative strains of
each clonal group, as described elsewhere (22). The allel-
ic profile of each strain was obtained by sequencing inter-
nal fragments of 7 housekeeping genes (arcC, aroE, glpF,
gmk, pta, tpi, yqiL) and entering them on the MLST home
page (http://saureus.mlst.net), where 7 numbers depicting
the allelic profile were assigned that defined a ST (22).
Similar STs were grouped into clonal complexes (CC).
Results
agr and STs
The 469 PVL-positive CA-MRSA isolates were agr
type 1 (n = 46, 9.8%), agr2 (n = 9, 1.9%), or agr3 (n = 414,
88.3%); none was agr4 (Table 1). The 469 PVL-positive
isolates belonged to 11 STs: the agr1 isolates were ST8,
ST59, ST22, ST766, or ST377; the agr2 isolates were all
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ST5; and the agr3 isolates were ST80, ST30, ST37, ST93,
or ST1 (Table 1). None of the STs were shared by different
agr types. The most frequent ST was ST80 (n = 357,
76.1%), which corresponded to the European clone.
spa Types and spa Clonal Complexes
The spa types were specific for agr type and ST. Minor
variations of spa types (deletions or duplications of SSR
units) were observed in several isolates within the same ST.
For instance, 9 spa types were recognized among the 357
ST80 isolates, but t044 was the major spa type (n = 333,
93.3%); 8 of these spa types belonged to the same spa CC.
A unique spa CC corresponded to each ST, except for ST1
isolates, which formed 3 different spa CC (Table 1).
Geographic Origin and Spread
A previous study (4) showed a limited number of
clones and a limited geographic distribution.
Schematically, ST80 was detected in Europe, ST8 and ST1
in the United States, and ST30 in Oceania. The results of
our study suggest intercontinental exchanges of several
clones (Table 1): 1) the ST8 clone (USA300) from the
United States toward Europe; 2) the ST1 clone (USA400)
from the United States toward Europe and Asia; 3) the
ST59 clone (USA1000) from the United States toward
Asia; 4) the ST80 clone from Europe toward Asia (12); and
5) the ST30 clone from Oceania toward Europe. Countries
with numerous international exchanges (e.g., Singapore)
have the highest clonal diversity.
New clones have been detected since 2003. One,
ST22, has been found in Europe only. Another new clone,
ST766, which belongs to the same CC (CC22) as ST22,
was found in Singapore (12). Clone ST377 (with a type V
SCCmec) was reported simultaneously in Europe and
Australia (3). Clone ST5 was detected in Europe only.
Clone ST93 (the Queensland clone), described in
Australia before 2003, has not yet been detected in other
countries (11).
Toxin Gene Content
The toxin gene distributions were compared to deter-
mine the genetic background of the different clones with
minor variations. For instance, ST80 isolates were all pos-
itive for etd, lukS-PV, lukF-PV, and edinA/B/C; very few
lacked lukDE or hlgv or harbored hlB (Table 2).
Superantigenic toxin genes were detected in isolates that
belonged to the different STs, except for ST377, ST80, and
ST93 (Table 2).
Antimicrobial Drug Resistance
Isolates of each ST were grouped according to the
number of antimicrobial drug resistance determinants they
harbored. Initial PVL-positive CA-MRSA isolates were
susceptible to most antimicrobial agents. For instance, 8 of
the 25 ST8 isolates included in this study between 2003
through 2005 were resistant to penicillin and oxacillin
alone, as were 17 of the 32 ST1 isolates and 18 of the 20
ST30 isolates (Online Appendix Table, available at
www.cdc.gov/EID/content/13/4/594-appT.htm). ST80 iso-
lates were initially resistant to penicillin, oxacillin,
kanamycin, and tetracycline, and intermediate to fusidic
acid. Since 2003, new antimicrobial resistance determi-
nants have been acquired (e.g., gentamicin and ofloxacin).
One ST8 isolate was resistant to penicillin, oxacillin,
kanamycin, erythromycin, tetracycline, and ofloxacin; 1
ST1 isolate was resistant to penicillin, oxacillin,
kanamycin, tobramycin, and gentamicin. A few ST80 iso-
lates from Algeria were resistant to multiple antimicrobial
agents. Most PVL-positive CA-MRSA strains with multi-
ple antimicrobial resistant determinants were detected in
Asia (Singapore, People’s Republic of China) or Africa
(Algeria).
Antimicrobial Resistance Genes
Antimicrobial resistance genes were sought in a sub-
set of 153 ST80 isolates. The aph3′-III gene, which
encodes high-level resistance to kanamycin and neomycin
but also to amikacin and isepamycin, was detected in all
153 isolates (100%). The tetK efflux gene was detected in
125 (82%) of tetracycline-resistant isolates. The ermC
gene, an erythromycin ribosome methylase, was detected
in 61 (40%) of erythromycin-resistant isolates. The far-1
gene was detected in 133 (87%) of fusidic acid–intermedi-
ate isolates.
SCCmec Types
SCCmec type was determined for 22 agr1 isolates (10
ST8, 1 ST59, 1 ST22, and 10 ST377); 5 agr2 isolates
(ST5); 190 agr3 isolates (179 ST80, 9 ST30, 2 ST93, and
7 ST1). All the isolates were SCCmec type IV, except for
the 10 ST377 isolates, which were SCCmec type V.
Discussion
This study has several findings. First, the continent-
specific clones of PVL-positive CA-MRSA described in
2003 by Vandenesch et al. (4) have now spread to other
continents. For instance, the ST1 clone USA400 is now
detected in Europe and Asia. Some PVL-positive clones,
such as ST1 and ST30, can now be considered pandemic,
as they are detected in America, Europe, and Asia. Second,
on a given continent, PVL-positive CA-MRSA have
spread from country to country. For instance, in Europe,
PVL-positive CA-MRSA were recently detected in
Slovenia, Romania, and Croatia. Third, new PVL-positive
CA-MRSA clones are emerging in strains with different
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genetic backgrounds. While most of the clones described
in 2003 by Vandenesch et al. (4) had an agr3 background,
the newly described clones are agr1 or agr2. Fourth, PVL-
positive CA-MRSA, which were initially susceptible to
most antistaphylococcal antimicrobial agents, have
acquired new antimicrobial resistance determinants, to
gentamicin and ofloxacin, for instance.
The global ST distribution of PVL-positive CA-
MRSA isolates in this study depends, of course, on the
sources of the isolates received by the French National
Reference Center for Staphylococci and does not reflect
the current epidemiology. Our collection represents a pas-
sive surveillance study and is related to the increased atten-
tion paid to CA-MRSA by certain regions. Nevertheless,
our results agree with other reports which confirm that
ST80 is mainly found in Europe (e.g., Denmark [7],
Finland [27], and Greece [24]), but also in Libya (28);
ST30 is pandemic (34).
PVL-negative, hospital-acquired MRSA belong to 5
major CCs (CC5, CC8, CC22, CC30, CC45). PVL-posi-
tive CA-MRSA of the same clonal classes were also
detected in our study, with the exception of CC45, but the
PVL + MRSA strains showed a broader CC diversity. For
instance, none of the ST80 isolates belonged to CCs har-
boring hospital strains. PVL-positive CA-MRSA are grad-
ually causing an increasing number of hospital-acquired
infections in countries, such as the United States, where
their prevalence is high (35). Kourbatova et al. reported
that, during the period 2003–2004, five prosthetic joint
infections were caused by USA300 strains (36).
The worldwide spread of PVL-positive CA-MRSA is
likely related to international travel. ST80 isolates recov-
ered in France were mainly detected in patients who were
originally from Algeria, a country that reported a high rate
of community- and hospital-acquired infections due to
ST80 isolates in 2006 (37). Maier et al. recovered ST22
strains from Turkish migrants in Germany (38).
Acquisition of new antimicrobial resistance determinants
could be related to misuse of antimicrobial agents; the
spread of multidrug-resistant strains could be facilitated by
poor hygiene, regardless of country.
It is not known whether PVL-positive CA-MRSA
clones arose through acquisition of the PVL phage by
strains with a methicillin resistance background or, con-
versely, through acquisition of the SCCmec element by
strains with a PVL-positive background. On analyzing the
database of the French National Reference Center for
Staphylococci, which contains >5,000 toxin gene profiles,
we found isolates that were related to the PVL-positive
MRSA clone ST80 but lacked either the PVL genes (5 iso-
lates) or the mecA gene (7 isolates) (data not shown).
These isolates, like the ST80 clone, were agr3, etd+,
edinA/B/C+; 1 isolate (PVL– mecA+) was ST80, and
another (PVL+ mecA–) was ST635 (a single-locus variant
of ST80). These “atypical” isolates were discovered in
Algeria, Switzerland, and France. We are unable to state
whether they are ancestors or descendants of the most
prevalent strains.
Deep-seated infections due to PVL-positive S. aureus
can be extremely severe. For example, necrotizing pneu-
monia carries a mortality rate close to 75% (39). Whether
the pathogenesis of these acute infections is related to the
effect of PVL alone or in combination with other virulence
factors such as superantigenic toxins is unclear. We found
that some PVL-positive CA-MRSA clones (ST80) lacked
any superantigenic toxin genes. Among the S. aureus viru-
lence factors (not screened for here), ST30 strains harbor
the bbp gene, which encodes bone sialoprotein (34). The
SCCmec elements detected in our collection were type IV
or V and corresponded to the smallest SCCmec element.
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PVL-positive CA-MRSA are usually susceptible to
most antistaphylococcal antimicrobial agents. Clone ST80
is usually resistant to tetracycline (mediated by the tetK
gene), intermediate to fusidic acid (far1 gene), and resist-
ant to kanamycin (aph3′-III gene). We observed the emer-
gence of rare isolates with multiple resistances to
antimicrobial agents such as gentamicin and ofloxacin.
From the therapeutic viewpoint, all the isolates were sus-
ceptible to trimethoprim-sulfamethoxazole, glycopeptides,
and linezolid.
The involvement of PVL in CA-MRSA infections has
not been proved in mouse sepsis and abscess models
developed by Voyich et al.: isogenic PVL-negative strains
of USA300 and 400 were as lethal as wild-type strains, and
they caused comparable skin diseases (40). Other experi-
ments have to be conducted to determine if PVL is secret-
ed in such a model.
In summary, since 2003 we have observed an impres-
sive worldwide spread of PVL-positive CA-MRSA clones
initially described at the beginning of this decade, and we
have also detected PVL-positive CA-MRSA strains of
other lineages. To counter this emerging global threat to
public health, systematic surveillance of both hospital and
community isolates is required, together with measures
designed to limit their spread.
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